EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials

Jean-Frédéric Colombel iD, Silvio Danese iD, Stefan Schreiber iD, Bruce E Sands iD, Andres J Yarur iD, Aram Kang iD, Dong-Hyeon Kim iD, Young Nam Lee iD, Stephen B Hanauer iD

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70205 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Jean-Frédéric Colombel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Colitis, Ulcerative, Crohn Disease, Gastrointestinal Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Celltrion Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims LIBERTY‐CD and LIBERTY‐UC demonstrated superior efficacy of subcutaneous infliximab (IFX SC) to placebo in patients with Crohn's disease (CD) or ulcerative colitis (UC). Here, we investigated the impact of anti‐drug antibodies (ADAs) on clinical outcomes.

Methods

Patients randomized to IFX SC maintenance treatment in the LIBERTY trials were included (CD, n = 231; UC, n = 294). ADAs were tested using a highly sensitive, drug‐tolerant assay. Patients were grouped by ADA occurrence and titer and evaluated for outcomes up to Week (W) 54.

Results

Among patients with CD and UC, 150 (64.9%) and 187 (63.6%) were ADA‐positive, respectively. No statistically significant differences were observed between the ADA‐positive and ADA‐negative groups in W54 efficacy (CD: clinical remission, 69.5% [95% confidence interval: 61.6–77.5] vs. 79.7% [70.2–89.2], p = 0.134; endoscopic response, 57.5% [48.9–66.1] vs. 65.2% [54.0–76.5], p = 0.359; UC: clinical remission, 49.1% [41.3–56.8] vs. 57.0% [46.5–67.4], p = 0.284), drug persistence (CD: 84.7% [79.1–90.6] vs. 85.2% [77.8–93.3]; UC: 84.5% [79.5–89.8] vs. 77.6% [70.1–85.9]), and safety (patients with ≥ 1 treatment‐emergent adverse event; CD: 71.2% [64.0–78.3] vs. 74.4% [64.9–83.8]; UC: 69.5% [62.9–76.0] vs. 64.2% [55.0–73.3]), despite lower drug concentrations in ADA‐positive patients at W54 (CD: 10.6 μg/mL [9.1–12.2] vs. 17.9 μg/mL [15.8–20.1]; UC: 12.2 μg/mL [10.8–13.5] vs. 21.0 μg/mL [18.4–23.6]). No significant relationship between ADA titer and efficacy or persistence was noted.

Conclusions

Although ADAs affected drug levels, no significant differences by ADA occurrence were observed in W54 efficacy or safety among patients receiving IFX SC maintenance treatment. While high ADA titers were associated with lower drug levels, effectiveness was not diminished within 1 year. Trial Registration ClinicalTrials.gov identifiers NCT03945019 (LIBERTY‐CD) and NCT04205643 (LIBERTY‐UC)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntibodiesColitis, UlcerativeCrohn DiseaseGastrointestinal AgentsInfliximabAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodInjections, SubcutaneousRemission InductionSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

CT‐P13Crohn's diseaseimmunogenicityinflammatory bowel diseaseinfliximab‐dyybsubcutaneous infliximabulcerative colitis

Substanzen

AntibodiesGastrointestinal AgentsInfliximab

Autor:innen und Institutionen

  • Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Gastroenterology, IRCCS San Raffaele Hospital and Vita-Salute University, Milan, Italy.
  • Department of Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.
  • F. Widjaja Inflammatory Bowel Disease Institute, Cedars Sinai Medical Center, Los Angeles, California, USA.
  • Global Medical Division, Celltrion Inc., Incheon, Republic of Korea.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

ORCID-Profile: Jean-Frédéric Colombel, Silvio Danese, Stefan Schreiber, Bruce E Sands, Andres J Yarur, Aram Kang, Dong-Hyeon Kim, Young Nam Lee, Stephen B Hanauer

Förderung

  • Celltrion Inc.

Zitieren

APA

Colombel, J. F., Danese, S., Schreiber, S., Sands, B. E., Yarur, A. J., Kang, A., Kim, D. H., Lee, Y. N., & Hanauer, S. B. (2026). Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70205

Vancouver

Colombel JF, Danese S, Schreiber S, Sands BE, Yarur AJ, Kang A, et al. Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70205

BibTeX
@article{Colombel2026,
  author = {Colombel, Jean-Frédéric and Danese, Silvio and Schreiber, Stefan and Sands, Bruce E and Yarur, Andres J and Kang, Aram and Kim, Dong-Hyeon and Lee, Young Nam and Hanauer, Stephen B},
  title = {Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate‐to‐Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70205}
}
Kostenlos starten →